Corporate News
Freenome (FRNM) Trading Update
During a 24‑hour period concluding at 09:05 AM Central Europe on Wednesday, 21 January 2027, Freenome’s shares advanced 6.98 %. The current market price sits at USD 14.06 per share on major exchanges. With a free float of 107.2 million shares, the company’s market capitalization is approximately USD 1.3 billion. In the past 24 hours, the trading volume reached USD 8.2 million, a modest figure given the company’s size. Over the previous month, however, the stock has depreciated by ‑24.28 %.
The 200‑day simple moving average stands at USD 12.52, indicating that the present price sits above its long‑term trend. Over the last 52 weeks, the share has traded between USD 9.95 (low on 13 July 2026) and USD 17.50 (high on 21 September 2026), placing the current price roughly 60 % above the 52‑week low.
Peer Performance (Past 24 Hours)
| Ticker | Change | Current Price | Market Cap (USD bn) |
|---|---|---|---|
| KLRA | +1.6 % | USD 12.89 | 1.5 |
| OCUL | ‑8.44 % | USD 6.65 | 1.5 |
| AZTA | +2.2 % | USD 35.73 | 1.5 |
| GPCR | +4.41 % | USD 22.88 | 1.5 |
| INVA | +1.44 % | USD 21.28 | 1.5 |
Innoviva (INVA) reports a price‑earnings ratio of 4.82, suggesting that the market values the company at a modest multiple relative to earnings.
Related Company Update
Basilea Pharmaceutica Ltd has announced that key data from its phase‑3 antifungal program—fosmanogepix (the azole isavuconazole, marketed as Cresemba®) and the antibacterial ceftobiprole (Zevtera®)—will be presented at the forthcoming IDWeek conference in Washington, D.C. The program will feature oral presentations covering pediatric data from the fosmanogepix Expanded Access Program, studies on manogepix activity against Candida auris and other moulds, as well as comparative analyses of isavuconazole with other azoles. Parallel sessions will address hepatotoxicity signals, pediatric and transplant use, and ceftobiprole dosing and in‑vitro activity against contemporary isolates. The company emphasized its commitment to addressing unmet needs in severe bacterial and fungal infections, noting that the development programs receive partial support from U.S. federal agencies. No additional financial disclosures were made.
